Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Huai-Che Shih"'
Autor:
Yen-Wei Chen, Kanako J. Nagatomo, Hollie E. Walsh, Brian W. Hanak, Taylor Anne Wilson, Huai-Che Shih, Jenovie M Hsia, Tzu-Chian Yang
Publikováno v:
Expert review of medical devices. 18(7)
Computer-assisted surgery (CAS) is a broad surgical methodology that utilizes computer technology to both plan and execute surgical intervention. CAS is widespread in both medicine and dentistry as it allows for minimally invasive and precise surgica
Autor:
Michael Eaddy, Todd Williamson, Sari Hopson, Anneliese LaRose, Huai-Che Shih, Linnea Tennan Tennant, Jennifer Cameron, Jason Lott
Publikováno v:
Journal of drugs in dermatology : JDD. 19(3)
Objective To assess differences in patient-reported treatment side effects and concerns associated with azelaic acid 15% foam (AAF) vs metronidazole cream (MC) and metronidazole gel (MG). Methods This study used matching-adjusted indirect comparison
Publikováno v:
The American journal of managed care. 26(5)
Objectives Exacerbations account for the greatest proportion of costs associated with chronic obstructive pulmonary disease (COPD). Here we aimed to evaluate, from the US payer perspective, the costs associated with moderate and severe COPD exacerbat
Autor:
Marlo Blazer, Jill A Bell, Michael Eaddy, Robert J. Fram, Augustina Ogbonnaya, Eileen Farrelly, Huai-Che Shih, Aaron Galaznik, Douglas V. Faller
Publikováno v:
PharmacoEconomics Open
Background and Objective Significant clinical burden is associated with higher-risk myelodysplastic syndromes (HR-MDS); however, the economic burden has not been fully examined. We examined cost of care and healthcare utilization (HCU) in HR-MDS pati
Autor:
Huai-Che Shih, Michael Eaddy, Harris A. Ahmad, Lois Lamerato, Kwanza Price, Rick Szymialis, Augustina Ogbonnaya
Publikováno v:
Journal of Medical Economics. 21:231-240
Anti-cyclic citrullinated peptide (CCP) antibody positivity is an established diagnostic factor for severe disease activity and joint damage and a prognostic factor for aggressive disease in rheumatoid arthritis (RA).To compare RA-related treatment,
Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson’s disease
Autor:
Clément François, Adam Ziemann, Amy Duhig, Italo Biaggioni, Eileen Farrelly, Huai-Che Shih, Cyndya A. Shibao, Augustina Ogbonnaya
Publikováno v:
Journal of Medical Economics. 20:525-532
To compare patient characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD plus neurogenic orthostatic hypotension (PD + nOH).MarketScan Commercial and Medicare Supplemental databases
Autor:
Huai-Che Shih, Augustina Ogbonnaya, Laurie Hamilton, Kristin Hennenfent, Vicki A. Morrison, Jill A Bell, Yaping Shou, Michael Eaddy, Aaron Galaznik
Publikováno v:
Future oncology (London, England). 14(25)
Aim: Evaluate healthcare costs and utilization of treated diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients. Materials & methods: Adults with newly diagnosed DLBCL and FL between 1 January 2008 and 31 October 2015 were ident
Autor:
Huai-Che Shih, Paul Lee, Allen R. Nissenson, Mark Desmarais, Michael Tuffli, Mahesh Krishnan, Fadi Almachraki
Publikováno v:
Population health management. 19(1)
This study assessed the hypothesis that the clinic site of service socioeconomic status (SES) represents an unmeasured confounder for clinical outcome comparisons between dialysis clinics and provider types, using data from the federal pay-for-perfor
Autor:
Amy Duhig, Clément François, Huai-Che Shih, Cyndya A. Shibao, Eileen Farrelly, Adam Ziemann, Italo Biaggioni, Augustina Ogbonnaya
Publikováno v:
Journal of Medical Economics. 20:1216-1216
Francois C, Biaggioni I, Shibao C, Ogbonnaya A, Shih H-C, Farrelly E, Ziemann A and Duhig A. Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson’s disease. Jo...
Autor:
Aaron Galaznik, Jill A Bell, Bruce J. Dezube, Michael Eaddy, Brian Seal, Huai-Che Shih, Marlo Blazer, Eileen Farrelly
Publikováno v:
Journal of Clinical Oncology. 35:247-247
247 Background: Treatment decisions in MDS are based on a prognostic scoring system that divides pts into five distinct risk categories (NCCN 2016). Treatment guidelines for HR MDS pts include hypomethylating agents (HMAs) alone (azacitidine & decita